On May 22, 2025, Evernorth announced it reached deals with Novo Nordisk and Eli Lilly to cap GLP-1 copays, including for Wegovy, at $200 per month. These agreements aim to make popular weight-loss drugs more affordable for eligible patients.
The initiative by Evernorth, a Cigna (TICKER:CI) subsidiary, is expected to expand access to Wegovy for millions of Americans. By reducing out-of-pocket costs, this partnership can encourage higher prescription uptake and adherence.
This collaboration strengthens Novo Nordisk's market access strategy by securing favorable formulary terms. It helps to address the cost barrier for patients and reinforces the company's commitment to broad availability of its obesity treatments.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.